Cytokinetics, Incorporated
CYTKHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeCytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating. The company carries a $10.42B market cap, placing it firmly in the large-cap category. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Market Cap
$10.42B
Beta
0.38
P/E (TTM)
—
P/E (Fwd)
-16.15
EPS (TTM)
$-6.85
EPS (Fwd)
$-4.75
ROE
—
ROA
-31.5%
Cash
$818.6M
Total Debt
$1.44B
Free CF
-$381.1M
52W Change
145.9%
Annual Financials
Cash vs Debt
The company holds $818.6M in cash, though total debt stands at $1.44B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$381.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been relatively flat, moving from $94.6M (2022) to $88.0M (2025).
CYTK's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cytokinetics, Incorporated and its sector.